SYK - Stryker Corporation

NYSE - NYSE Delayed Price. Currency in USD
205.40
-0.09 (-0.04%)
At close: 4:02PM EDT
Stock chart is not supported by your current browser
Previous Close205.49
Open206.27
Bid0.00 x 1200
Ask205.40 x 900
Day's Range205.08 - 206.91
52 Week Range144.75 - 210.85
Volume706,392
Avg. Volume1,161,537
Market Cap76.781B
Beta (3Y Monthly)1.01
PE Ratio (TTM)22.15
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield2.08 (1.01%)
Ex-Dividend Date2019-06-27
1y Target EstN/A
Trade prices are not sourced from all markets
  • Will Abbott's (ABT) Q2 Earnings Gain From Overall Growth?
    Zacks2 days ago

    Will Abbott's (ABT) Q2 Earnings Gain From Overall Growth?

    Abbott's (ABT) consistent rise on a strong Diabetes Care business performance is seen over the last few quarters.

  • Zacks.com featured highlights include: Stryker, T. Rowe, Applied Materials, Fiat and Northrop
    Zacks5 days ago

    Zacks.com featured highlights include: Stryker, T. Rowe, Applied Materials, Fiat and Northrop

    Zacks.com featured highlights include: Stryker, T. Rowe, Applied Materials, Fiat and Northrop

  • Why Stryker (SYK) Could Beat Earnings Estimates Again
    Zacks5 days ago

    Why Stryker (SYK) Could Beat Earnings Estimates Again

    Stryker (SYK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

  • Should You Be Worried About Insider Transactions At Stryker Corporation (NYSE:SYK)?
    Simply Wall St.5 days ago

    Should You Be Worried About Insider Transactions At Stryker Corporation (NYSE:SYK)?

    We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...

  • AngioDynamics (ANGO) Q4 Earnings Miss, Revenues Top Estimates
    Zacks6 days ago

    AngioDynamics (ANGO) Q4 Earnings Miss, Revenues Top Estimates

    AngioDyamics (ANGO) gains from solid segmental contributions in fourth-quarter fiscal 2019.

  • 5 ROE Stocks to Profit as Fed-Fueled Rate Cut Hopes Soar
    Zacks6 days ago

    5 ROE Stocks to Profit as Fed-Fueled Rate Cut Hopes Soar

    ROE helps investors distinguish profit-generating companies from profit burners and is useful in determining the financial health of a company.

  • Analysts bullish on Boston Scientific's plans for 75 new products by 2022
    American City Business Journals14 days ago

    Analysts bullish on Boston Scientific's plans for 75 new products by 2022

    Boston Scientific CEO Michael Mahoney laid out the long-term strategy for the company late last week, including a plan to launch 75 new cardiac valve, brain stimulation and other products by 2022.

  • Best Places to Work winner Stryker Corp. is international firm with local approach
    American City Business Journals20 days ago

    Best Places to Work winner Stryker Corp. is international firm with local approach

    Stryker is an international health-care-technology firm traded on the NYSE (SYK) that has about 36,000 employees globally, and a large-enough Colorado presence that it ranked No. 1 in the Extra-Large category in Denver Business Journal's 2019 Best Places to Work awards program. Its 244 metro-area employees enjoy a generous benefits package that includes 401(k) matching into the double digits — most employees who put at least 8% of their income toward a retirement plan will see an 11% company contribution, when you include Stryker's annual discretionary match. The company also purchased electric scooters for its Greenwood Village office.

  • Should You Be Adding Stryker (NYSE:SYK) To Your Watchlist Today?
    Simply Wall St.20 days ago

    Should You Be Adding Stryker (NYSE:SYK) To Your Watchlist Today?

    It's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks...

  • How To 'De-Risk' Your Stock Portfolio For A Crash
    Investopedia22 days ago

    How To 'De-Risk' Your Stock Portfolio For A Crash

    Equity investors looking to lower their portfolio risk should pursue a multifaceted approach and not just rush into bonds.

  • Moody's23 days ago

    Stryker Corporation -- Moody's announces completion of a periodic review of ratings of Stryker Corporation

    Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of Stryker Corporation. Global Credit Research- 24 Jun 2019. New York, June 24, 2019-- Moody's Investors Service ...

  • What's in Store for Patterson Companies (PDCO) in Q4 Earnings?
    Zacks26 days ago

    What's in Store for Patterson Companies (PDCO) in Q4 Earnings?

    Patterson Companies (PDCO) expects to gain from the Animal Health unit in fourth-quarter fiscal 2019.

  • Here's Why You Should Hold on to Stryker (SYK) Stock Now
    Zacks28 days ago

    Here's Why You Should Hold on to Stryker (SYK) Stock Now

    Stryker (SYK) is gaining steadily from strong international growth and robust product portfolio. However, unfavorable pricing environment remains a woe.

  • These Are the Top CEOs (According to Employees)
    Motley Fool28 days ago

    These Are the Top CEOs (According to Employees)

    The top performers have at least a 99% approval rate.

  • Why Dividend Hunters Love Stryker Corporation (NYSE:SYK)
    Simply Wall St.last month

    Why Dividend Hunters Love Stryker Corporation (NYSE:SYK)

    Could Stryker Corporation (NYSE:SYK) be an attractive dividend share to own for the long haul? Investors are often...

  • The Zacks Analyst Blog Highlights: Intel, Altria, Stryker, Sherwin-Williams and Verisk
    Zackslast month

    The Zacks Analyst Blog Highlights: Intel, Altria, Stryker, Sherwin-Williams and Verisk

    The Zacks Analyst Blog Highlights: Intel, Altria, Stryker, Sherwin-Williams and Verisk

  • Top Stock Reports for Intel, Altria & Stryker
    Zackslast month

    Top Stock Reports for Intel, Altria & Stryker

    Top Stock Reports for Intel, Altria & Stryker

  • Is Stryker Corporation (SYK) A Good Stock To Buy?
    Insider Monkeylast month

    Is Stryker Corporation (SYK) A Good Stock To Buy?

    With the first-quarter round of 13F filings behind us it is time to take a look at the stocks in which some of the best money managers in the world preferred to invest or sell heading into the first quarter. One of these stocks was Stryker Corporation (NYSE:SYK). Is Stryker Corporation (NYSE:SYK) the right pick […]

  • What's in the Offing for HEXO Corp's (HEXO) Q3 Earnings?
    Zackslast month

    What's in the Offing for HEXO Corp's (HEXO) Q3 Earnings?

    HEXO Corp's (HEXO) recent 1,000,000 sq. ft. greenhouse expansion is likely to reflect on quarterly results.

  • Markitlast month

    See what the IHS Markit Score report has to say about Stryker Corp.

    Stryker Corp NYSE:SYKView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for SYK with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting SYK. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding SYK totaled $4.16 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • 5 Healthcare Stocks to Pick Up From the Wreckage
    InvestorPlacelast month

    5 Healthcare Stocks to Pick Up From the Wreckage

    Once loved, healthcare stocks are quickly becoming some of the most hated stocks on the planet. It's easy to understand why. Rising drug and procedure costs have made many healthcare stocks targets for various political pundits and presidential candidates. The growing calls for Medicare-For-All and/or socialized medicine has the potential to hit many healthcare firms right in the pocket. When coupled with the general market sell-off, the fast-moving healthcare sector has been a real downer.But that has only made the sector prime for bargain shopping.Even with calls for increased regulation, the healthcare sector still has great long-term potential. Thanks to rising global demand, aging populations as well as new high-tech and high-margined therapies, there are lots of levers for the sector to pull in order to keep the profits coming. And while some healthcare stocks will be hit hard in the regulation wave (like insurance and pharmacy benefit managers), many will be just fine. This could make the recent declines a tantalizing buy-in point for portfolios.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 10 Stocks to Buy That Could Be Takeover Targets With the long-term in mind, here are five healthcare stocks that are worth picking up from the wreckage. Abiomed (ABMD)Source: Shutterstock There's a good chance that you've never heard of Abiomed (NASDAQ:ABMD). The firm was only added to the S&P 500 about a year ago. But in that time, it has grown immensely in terms of fundamentals and share price.ABMD produces the Impella, which is the world's smallest heart pump. The device is minimally invasive. That's a key selling point for doctors. Open-heart surgery is risky to begin with, but especially so for patients who have suffered some sort of major cardiovascular event. Impella eliminates many of the risks. Meanwhile, the device can be configured in a variety of applications. Because of this, the Impella is quickly becoming the standard of care for doctors in cardiac surgery.As a result, sales of the device continue to surge. For full-year 2018 results, ABMD managed to see a 30% jump in sales and nearly 43% increase in profits based on continued demand for the game-changing device. And yet, the runway is still long for the firm. There's plenty of market share in the U.S. to gain from older heart pump devices and global demand is still in its infancy. Meanwhile, the firm continues to attract plenty of buyout/M&A buzz and would be a wonderful tuck-in deal for many larger device stocks.However, shares of ABMD are about 35% below their all-time highs from last year. And it isn't cheap from a price-to-earnings perspective either. ABMD is a classic growth stock, but the recent dip makes for an interesting buy-in for those willing to hold it over the long term. Teledoc (TDOC)Source: MayApps207 via WikiMedia Saving money and reducing costs is exactly what any pending regulation in the sector will be all about. That's great news for Teledoc (NASDAQ:TDOC). The firm is the largest player in the growing telemedicine field. Here, patients can fire-up their tablets, PCs or smartphones and speak to a physician in real time, get a diagnosis and even send a prescription to their local pharmacy.Health insurers, benefit managers, employers and consumers seem keen on the idea. More employers are adding the service to their benefits package, with more than 40% of the Fortune 500 offering it in their benefits.This has allowed TDOC to experience some very fast growth over the last few years. between 2016 and what its estimated to pull in this year, Teledoc has seen a staggering 64% compound annual growth rate in terms of revenues. Meanwhile, the firm is finally starting to turn those revenues into meaningful and growing profits.And the growth could continue. TDOC has moved into the mental health arena and has been smartly buying smaller rivals to add instant market share. Meanwhile, more companies continue to see the benefits of adding the platform to their Human Resources package. * The 10 Best Stocks for 2019 -- So Far All in all, TDOC is a high growth healthcare stock that is now trading much lower than expected. Amgen (AMGN)Source: Shutterstock As one of biotech and healthcare's elder statesmen, Amgen (NASDAQ:AMGN) has been hit hard over the last year on drug pricing news. Key blockbusters like Enbrel and Neulasta are two of the most prescribed drugs in their categories and mint cash for AMGN. Those blockbusters, as well as others, such as Repatha, blood-cancer drug Kyprolis and bone-density drug Prolia, are the reasons why Amgen has become a dividend and buyback stalwart. Their high prices are also the reason why AMGN is in the crosshairs of lawmakers.Despite that and the drop in AMGN stock, investors may want to consider the firm.For one thing, Amgen continues to dive head first into more advanced cancer and gene therapy drugs. These specialized drugs are naturally higher cost. There's very little that regulation can do for them. With data from Amgen's new cancer therapies crushing the trial, there's a good chance that the firm will have another blockbuster in its arsenal. And we can't forget about its massive pipeline either.In the end, AMGN will be pretty immune from the effects of regulation and will continue to rack up massive cash flows from specialized drugs. That should help pad its now 3.32% dividend for years to come. Stryker Corporation (SYK)Source: Shutterstock Artificial knees, hospital beds and even specialized bone cement … medical device company Stryker (NYSE:SYK) has it all. And that could make it a top healthcare stock contender to snag-up in the recent sector wreckage. SYK has its hands in many pots and that will allow it to handle anything the government throws at it.This is evident by its continued surge in sales and revenues. Last quarter, SYK managed to see a big 8.5% jump in net sales. The key was that divisions featuring more high-tech devices and products, such as orthopedics and neurotechnology, saw big double-digit sales gains. The medical device firm has continued to boost these divisions with smart M&A as well as new innovative internal product launches. That's a good thing as these higher-tech areas are seen as being more insulated to regulation. For Stryker and its shareholders, this could be gold for the long haul.Speaking of that gold, SYK has been sharing the wealth with investors as well. The firm's latest dividend represents a big 11% increase. At the same time, Stryker has been a buyback champ as well -- reducing its share count by about $1 billion last year. * 10 Heavily Shorted Stocks to Sell -- Because the Bears Are Right With a forward P/E of 22, Stryker isn't super cheap, but considering its growth estimates and potential to keep the good times going in the face of regulation, that could seem like a bargain. Bristol-Myers Squibb (BMY)Source: A 4 via Flickr It's not surprising that old-school pharma has been hit hard in recent weeks. But there's nothing particularly old school about Bristol-Myers Squibb (NYSE:BMY). That's because BMY has quickly become the anti-cancer and advanced drug machine.BMY already had top blockbuster cancer-fighter Opdivo, which pulls in more than $2 billion in quarterly revenues for the firm. But thanks to its recent $74 billion out of Celgene (NASDAQ:CELG), Bristol-Meyers will have one of the richest oncology portfolios around. This includes blockbusters Yervoy, Revlimid and Pomalyst which will all now be under its umbrella. This doesn't even include CELG's rich pipeline nor BMY's own advanced cancer-fighting drugs under development.As we said before, specialized cancer drugs are big revenues drivers and given just how advanced they are, the government may have little ability to regulate them. This should help drive revenues and cash flows at Bristol-Meyer's for years to come. And yes, patent expiration for Revlimid is coming down the pike. But under BMY's vast portfolio of drugs, that expiration means less than when it was CELG's chief revenue driver.Yet, BMY trades at a real discount to other big healthcare stocks. For investors, the top and future cancer fighter offers a great long-term play at cheap prices.As of this writing, Aaron Levitt was long AMGN and ABMD. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * The 4 FANG Stocks Won't Be Bitten By Regulation Threats * 10 Stocks to Buy That Could Be Takeover Targets * 4 Big Bank Stocks Rebounding Compare Brokers The post 5 Healthcare Stocks to Pick Up From the Wreckage appeared first on InvestorPlace.

  • Stryker Corporation (NYSE:SYK) Earns A Nice Return On Capital Employed
    Simply Wall St.last month

    Stryker Corporation (NYSE:SYK) Earns A Nice Return On Capital Employed

    Today we'll look at Stryker Corporation (NYSE:SYK) and reflect on its potential as an investment. Specifically, we'll...

  • The Top Health Care Companies in the World
    Investopedia2 months ago

    The Top Health Care Companies in the World

    An introduction to health care companies that are tops in their fields. From health care provider to pharmaceuticals, these companies have the largest global presence according to market capitalization. Learn who these health care giants are and why they may be a good investment.

  • Can Segmental Growth Aid Cooper Companies' (COO) Q2 Earnings?
    Zacks2 months ago

    Can Segmental Growth Aid Cooper Companies' (COO) Q2 Earnings?

    Cooper (COO) expects to gain from CVI and CSI units in the fiscal second quarter.

  • Veeva Systems (VEEV) to Report Q1 Earnings: What's in Store?
    Zacks2 months ago

    Veeva Systems (VEEV) to Report Q1 Earnings: What's in Store?

    Top-line growth and solid show by Subscription services and Professional services units are likely to aid Veeva Systems (VEEV) in Q1 earnings. However, rising expenses remains a dampener.